Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2010 by Weill Medical College of Cornell University.
Recruitment status was:  Recruiting
Information provided by:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
First received: September 15, 2008
Last updated: October 27, 2010
Last verified: October 2010
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).

Diffuse Large B-cell Lymphoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • evaluating the predictive value of a positive PET scan early in the course of standard chemotherapy [ Time Frame: after 2 cycles of chemotherapy ]

Estimated Enrollment: 36
Study Start Date: May 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
All patients
All patients


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Newly diagnosed diffuse large b cell lymphoma patients planning to receive 6-8 cycles of R/CHOP chemotherapy.

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma
  • Patients must have received no prior anti-lymphoma therapy.
  • Age >18 years.
  • Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients who have known HIV infection.
  • Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00754117

United States, New York
Weill Cornell Medical College
New York, New York, United States, 10021
Sponsors and Collaborators
Weill Medical College of Cornell University
Principal Investigator: Rebecca Elstrom, MD Weill Medical College of Cornell University
  More Information

Additional Information:
Responsible Party: Dr. Rebecca Elstrom, Weill Cornell Medical College
ClinicalTrials.gov Identifier: NCT00754117     History of Changes
Other Study ID Numbers: 0801009588 
Study First Received: September 15, 2008
Last Updated: October 27, 2010

Keywords provided by Weill Medical College of Cornell University:
diffuse large b cell lymphoma
newly diagnosed

Additional relevant MeSH terms:
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on January 24, 2017